Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.
1. A method for intravenous administration of an ABDNAZ formulation to a patient suffering from cancer in order to treat the cancer, the method comprising intravenously administering to the patient in need thereof a therapeutically effective amount of an ABDNAZ formulation comprising at least 60% v/v of whole blood, 10 μg/mL to 1 mg/mL of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (“ABDNAZ”), and an anticoagulant, in order to treat the cancer.
2. The method of claim 1 , wherein the whole blood is autologous whole blood.
3. The method of claim 1 , wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 30 mL/hour.
4. The method of claim 1 , wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 60 mL/hour.
5. The method of claim 1 , wherein the cancer is a solid tumor.
6. The method of claim 1 , wherein the cancer is brain cancer, bladder cancer, breast cancer, cervical cancer, cholangiocarcinoma, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, or uterine cancer.
7. The method of claim 1 , wherein the cancer is a leukemia or lymphoma.
8. The method of claim 1 , wherein the ABDNAZ formulation consists of whole blood, ABDNAZ, an anticoagulant, and optionally one or more of water, a polyethylene glycol, and N,N-dimethylacetamide.
9. The method of claim 1 , wherein intravenous administration of the ABDNAZ formulation commences within about 1 hour after formation of the ABDNAZ formulation.
10. The method of claim 1 , further comprising obtaining an aliquot of whole blood from the patient, and then using said aliquot to prepare the ABDNAZ formulation for administration to the patient.
11. The method of claim 1 , wherein the patient has at least 95% of the amount of their average daily blood volume.
12. The method of claim 11 , wherein the whole blood is autologous whole blood.
13. The method of claim 11 , wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 30 mL/hour.
14. The method of claim 11 , wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 60 mL/hour.
15. The method of claim 11 , wherein the cancer is a solid tumor.
16. The method of claim 11 , wherein the cancer is brain cancer, bladder cancer, breast cancer, cervical cancer, cholangiocarcinoma, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, or uterine cancer.
17. The method of claim 11 , wherein the cancer is a leukemia or lymphoma.
18. The method of claim 11 , wherein the ABDNAZ formulation consists of whole blood, ABDNAZ, an anticoagulant, and optionally one or more of water, a polyethylene glycol, and N,N-dimethylacetamide.
19. The method of claim 1 , wherein any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation is no greater than Grade 2.